International Journal of Research and Review
Vol. 10; Issue: 11; November 2023
Website: www.ijrrjournal.com
Review Paper *E-ISSN: 2349-9788; P-ISSN: 2454-2237*

Genetic Factors Associated with Hypertension: A Comprehensive Review

Ramakrishna Shabaraya A[1], Trupthi D Shetty[2]

[1]Department of Pharmacy Practice, [2]Department of Pharmacy Practice,
Srinivas College of Pharmacy, Rajiv Gandhi University of Health Sciences, Mangaluru, India

Corresponding Author: Trupthi D Shetty

DOI: https://doi.org/10.52403/ijrr.20231115

ABSTRACT

Recent scientific findings indicate that hypertension is a largely genetically driven condition; one of today's leading global health issues. There are many identified gene mutations associated with different aspects involving blood pressure control that lead to hypertension. More recently, certain specific genetic variants related to blood pressure control have been found using the modern techniques of genetic analysis that may assist in developing custom strategies to prevent and treat hypertension.

The aim of this article is to highlight genetic aspects of hypertension and use them to establish individual therapy. It looks at the influence of genetic diversity on sodium resorption, skeletal muscle contraction, and drug pharmacokinetics. These studies indicate that GWAS has identified some genetic variants for hypertension and developed some genetic risk score (GRS) which can be used for prediction purpose.

Therefore, genetic contribution is significant in establishing as well as sustaining high blood pressure. Knowledge about genetics regarding hypertension may change the way it is addressed on a person-by-person basis. Nevertheless, research needs to tackle the challenge of validating associations among diverse populations while developing a mechanism for translating genetic findings into clinical practice. Thus, we would enhance preventive, diagnostic and therapeutic measures for many people globally.

Keywords: *Hypertension; Genetic factors; Blood pressure regulation; Genome-wide association studies (GWAS); Personalized medicine approaches.*

INTRODUCTION

Millions of people worldwide are affected with hypertension, often known as high blood pressure, which continues to be a major global health concern.[1] Around the world, hypertension is a key factor in premature death. The reduction of hypertension prevalence by 33% between 2010 and 2030 is one of the global targets for noncommunicable diseases. Globally, an estimated 1.28 billion people aged 30 to 79 years suffer from hypertension, with the majority (two-thirds) living in low- and middle-income countries. Adults suffering from high blood pressure are 46% less aware of their disease. Nearly one in five (21%) individual's who have hypertension have it under control.[2] Chronic stress, a poor diet, and sedentary habits have historically been linked to hypertension. The crucial importance of genetic variables in hypertension susceptibility has, however, been highlighted by new genetic study results. [3] The disease development is

complex and involves multiple causals in the form of gene-environment interplay which plays the key role. There are several factors that contribute significantly to an individual's vulnerability to high blood pressure, such as genetic factors.[4] Better insight into the genetic basis of this illness may assist in enhancing the treatment outcomes of patients by developing novel diagnostic methods. Knowledge about genetic factors is critical for many subject areas including medicine and biology. Such a deep understanding about certain genes that can contribute into different health problems and even affect an individual's physical appearance should be used as a tool for screening health risks and designing targeted medical approach. Additionally, gene studies may add a lot of information towards the understanding of how evolution works and about the variations that are common in different groups. To sum up, the knowledge of genetics represents a cornerstone in developing medical science and gaining insight into human genetics in general. [5-6]

This article focuses on exploring what genetic factors have to do with hypertension and what the prevalence of disease is seen across countries around the world as well other issues including genetic risks and the pathways through which genes affect blood pressure, clinical implications, methodology, and the main outcomes of studies reviewed This review reviews some recent advances on the genetics of hypertension as a guide toward future studies by considering their clinical relevance.

GENETICS AND HYPERTENSION

Hypertension can be developed due to genetic factors. Research has demonstrated the significance of genetic variations in the control of blood pressure and the etiology of hypertension. [7-8] Hypertension refers to an abnormal state of higher-than-normal measurements of SBP and DBP. However, thresholds of this condition differ between guidelines, but usually a blood pressure reading above 130/80 mmHg can be classified as hypertension. [9-10] This hypertension is a widespread issue with more than 1 billion people experiencing it all over The condition is found in different populations, but some ethnicities are more prone to it. Hypertension is a major cause of many cardiovascular diseases such as strokes, heart attack, kidney failures among others. [11] Studies from family and twins indicate that genetics play an important role in the development of this condition. [12] Approximately 30-50% of blood pressure variability is heritable.[12] It allows in identifying unique genetics risks that have been associated with the development of hypertension.

GENETIC RISK FACTORS

GENETIC POLYMORPHISMS ASSOCIATED WITH HYPERTENSION

Renin Angiotensin Aldosterone System Genes

A confluence of environmental and genetic factors contributes to the complicated disease of hypertension. The renin-angiotensin-aldosterone system (RAAS) is important for controlling blood stress and fluid-electrolyte equilibrium. Interventions aimed at treating high blood pressure usually centre on this system.[13] The RAAS genes, including angiotensinogen (AGT), angiotensin-converting enzyme (ACE), and angiotensin II type 1 receptor (AT1R), have been extensively studied in relation to hypertension. Numerous studies have reported associations between specific genetic polymorphisms within these genes

and increased hypertension risk.[14] For instance, the AGT M235T polymorphism [15] has been linked to elevated blood pressure levels and increased susceptibility to hypertension. Similarly, the ACE insertion/deletion (I/D) polymorphism has shown significant associations with hypertension, with the D allele being associated with higher blood pressure levels. Peripheral vascular disease (PVD) and polymorphisms in the renin-angiotensin system (RAS) genes have been the subject of numerous studies, although the results of these investigations have been inconsistent. Due to its functional importance, the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism [15-16] has received special attention among the assortment of RAS candidate gene variants. The ACE gene, which has 26 exons and 25 introns, is found on the long arm of human chromosome 17 (17q23). [17] The ACE I/D polymorphism is caused by the presence or lack of a 287-base pair Alu repeat sequence in intron 16 of the ACE gene (dbSNP rs1799752, chromosomal location 63,488,529 GRCh37).[18] It is known that the I/D (ACE I/D) polymorphism is responsible for almost half of the overall phenotypic variation of circulating (intracellular) and tissue (tissue) ACE in Caucasian individuals, with increased serum ACE levels and activity in carriers of the D allele. The DD genotype and D allele were also found to be strongly associated with hypertension in different populations [16-19]

In summary, four polymorphisms in the RAAS were chosen due to their importance in the pathophysiology of hypertension. Numerous disorders have been linked to the reference SNP identification (rs) of ACE, rs1799752, an insertion/deletion (I/D) polymorphism. The D allele is linked to an increased risk of hypertension and preeclampsia, among other conditions, due to its enhanced activity, which is unrelated to angiotensin II production.[20] Angiotensin II, a powerful vasoconstrictor, is produced when AGT is converted by ACE; M235T (rs699) is a nonfunctional polymorphism, but 235 is in linkage equilibrium with 6A.[21] In both transgenic mice and humans, elevated blood pressure is linked to the AGT haplotype 1 mutations 217A, 6A, +507G, and +1164A.21 Angiotensin II's prohypertensive impact is caused by AGTR1 being occupied, which causes vasoconstriction and sodium retention.[22] Hypertension is linked to polymorphisms of AGTR1, such as rs5186.[23] Aldosterone can elevate blood pressure via increasing vascular smooth muscle contractility and renal salt transport, among other mechanisms, via mineralocorticoid and non-mineralocorticoid receptors.[24] The genetic polymorphism CYP11B2 rs1799998 in aldosterone synthase, which is required to synthesise aldosterone, is linked to hypertension. [24-25] A subsequent meta-analysis, however, was unable to demonstrate a connection between the SNPs in the ACE, AGT, and CYP11B2 genes and hypertension.[26] Despite numerous attempts to connect ACE I/D polymorphism to HTN, the findings are still debatable.[27-29] The observed difficulties in obtaining uniformity within these research may be due to several methodological restrictions, including insufficient sample numbers, ethnic variety, potential selection biases, environmental impacts, and inherent population-specific variances.[30]

Endothelial Nitric Oxide Synthase (eNOS) Gene

Nitric oxide, a powerful vasodilator produced by the eNOS gene, is essential for controlling blood pressure.[31] Nitric oxide

generation may be hindered as a result of genetic abnormalities in the eNOS gene, which could eventually result in hypertension.[31]

The endothelial nitric oxide synthase enzyme, which is mostly expressed in the endothelial cells lining blood arteries, is encoded by the eNOS gene.[32] Nitric oxide (NO), a chemical that relaxes and dilates blood vessels and controls blood pressure, is produced in large part by this enzyme. [32-33]

As a vasodilator, nitric oxide relaxes the smooth muscles in blood vessel walls to increase blood flow. Additionally, it lessens the likelihood of arterial stiffness and hypertension by preventing the growth of vascular smooth muscle cells. As a result, maintaining normal blood pressure depends on appropriate nitric oxide generation.[34]

The eNOS gene's expression and function can be influenced by certain genetic variants, such as single nucleotide polymorphisms (SNPs).[35] The Glu298Asp polymorphism is the SNP that has been most thoroughly investigated in relation to hypertension. [36-37] This mutation has been linked to decreased eNOS activity and insufficient nitric oxide synthesis, which raises blood pressure.[38]

The association between eNOS gene polymorphisms and hypertension has been studied extensively. [39-40] According to research, those with the Glu298Asp polymorphism are more likely to develop hypertension than those without the variant.[41] T-786C and 4a/b are two more eNOS gene polymorphisms that have also been linked to elevated blood pressure levels.[42]

The importance of nitric oxide in controlling blood pressure has drawn attention to treatment strategies that target the eNOS pathway. Nitric oxide donors, eNOS activators, and eNOS gene therapy are some of the tactics being investigated to boost nitric oxide synthesis and bring blood pressure levels back to normal.[43] Understanding how the eNOS gene affects blood pressure control has significant clinical implications that make it possible to identify at-risk people early and provide them with individualised care. It is possible that additional study in this area will lead to the development of innovative therapeutic strategies for the efficient treatment of hypertension.

Alpha-Adducin (ADD1) Gene

The Alpha-Adducin (ADD1) gene exerts a notable influence on the initiation and advancement of hypertension, primarily affecting the regulation of blood pressure by modulating sodium reabsorption within the renal system.[44] Gaining insights into the genetic underpinnings of hypertension holds the potential to open doors for tailored therapeutic approaches and enhanced patient results.

Hypertension is a multifaceted condition influenced by genetic and environmental factors. The discovery of hypertension-related genes has spurred novel research and treatment prospects. The chromosome 4-based ADD1 gene, extensively investigated, plays a key role in blood pressure regulation.[45]

ADD1 gene, which produces alpha-adducin protein is pivotal for regulating sodium transport in kidney.[46] Increased sodium retention elevates blood volume, subsequently raising blood pressure, making sodium reabsorption a critical determinant of blood pressure.[47] Genetic changes in the ADD1 gene can disrupt alpha-adducin's sodium regulation, leading to elevated blood pressure.

Several genetic variants of the ADD1 gene have been identified, with the most studied

being the Gly460Trp polymorphism. [48-49] This variant has been associated with increased hypertension risk in various populations.[49] Individuals carrying the Trp allele exhibit enhanced sodium reabsorption, leading to higher blood pressure levels.[50] Understanding these genetic variants can aid in identifying individuals at higher risk for hypertension and implementing preventive measures.

Beta-Adrenergic Receptor (ADRB) Genes

The ADRB genes are central to the development and progression of hypertension, impacting blood pressure regulation, vascular tone, and responses to antihypertensive drugs.[51] These genes encode beta-adrenergic receptors, crucial for regulating the body's reaction to stress hormones like adrenaline and noradrenaline. Mainly located in the heart, lungs, and blood vessels, they control heart rate, contractility, and vascular tone. [52-53]

Numerous studies have pinpointed specific genetic variations within ADRB genes linked to a higher hypertension risk.54 For example, ADRB1 gene variant Arg389Gly associates with elevated blood pressure and hypertension susceptibility.[55] Similarly, ADRB2 gene variant Gly16Arg relates to altered receptor function and increased hypertension risk.[56]

ADRB genes influence blood pressure by affecting heart rate, cardiac output, and vascular tone. Gene variants can alter receptor function, impacting the body's response to stress hormones, leading to heightened sympathetic activity, vasoconstriction, and elevated blood pressure.[57] Furthermore, ADRB genes significantly influence individual responses to antihypertensive medications.[51] Genetic variations within these genes can affect the effectiveness and side effects of beta-blockers, a commonly prescribed antihypertensive class. For instance, certain ADRB1 gene variants may enhance beta-blocker response, while ADRB2 gene variants could reduce efficacy or lead to adverse reactions.[58] Genetic variations within these genes can increase an individual's susceptibility to hypertension and influence their response to treatment. By unraveling the intricate relationship between ADRB genes and hypertension, we can pave the way for personalized medicine approaches that target the underlying genetic factors contributing to this prevalent health condition.

Sodium and potassium transport genes [ATP1A1 and SLC12A2]

Sodium-Potassium ATPase Gene (ATP1A1):

The sodium-potassium ATPase gene regulates the movement of sodium and potassium ions across cell membranes. It maintains the electrochemical gradient necessary for various physiological processes, including nerve transmission and muscle contraction.[59] Dysregulation or mutations in ATP1A1 can disrupt the normal functioning of the sodium-potassium pump. This disruption leads to an imbalance in sodium and potassium levels, favoring sodium retention and potassium excretion.[60] Increased sodium retention contributes to extracellular fluid volume expansion, leading to elevated blood pressure. Decreased potassium excretion impairs vasodilation and promotes vasoconstriction, further exacerbating hypertension.[60]

Sodium-Potassium-Chloride Cotransporter Gene (SLC12A2)

The sodium-potassium-chloride cotransporter gene, known as SLC12A2,

plays a crucial role in facilitating the transportation of sodium, potassium, and chloride ions across cell membranes.[61] This gene is essential for maintaining the delicate balance of electrolytes and regulating blood pressure within the body. However, any dysregulation or mutations in the SLC12A2 gene can disrupt this balance, particularly affecting the reabsorption of sodium and potassium ions in the kidneys.[61] Consequently, this disruption can lead to altered blood pressure regulation. When the SLC12A2 gene is dysfunctional, it can result in an increased reabsorption of sodium and a decreased reabsorption of potassium in the kidneys. [61] This imbalance significantly contributes to fluid retention, vasoconstriction, and ultimately elevated blood pressure.[62] The intricate mechanism of the SLC12A2 gene is crucial for maintaining the proper electrolyte balance and ensuring the efficient functioning of the kidneys in regulating blood pressure.[62]

Understanding the scientific significance of the SLC12A2 gene is crucial for comprehending the mechanisms behind electrolyte balance and blood pressure regulation.

CANDIDATE GENES AND HYPERTENSION

ACE Gene

The RAAS is a complex hormonal system that regulates homeostasis of the body. The ACE gene encodes for the ACE enzyme, which converts angiotensin I to angiotensin II, a potent vasoconstrictor. Angiotensin II in turn stimulates the release of aldosterone, a hormone that promotes sodium and water retention, leading to increased blood volume and elevated blood pressure.[63]

The relationship between genetic variants in the ACE gene and hypertension has received substantial research. The insertion/deletion (I/D) polymorphism, which affects the presence or absence of a 287-base pair DNA fragment in intron 16 of the ACE gene, is one of the most well-known variations.[64] Higher ACE activity and an elevated risk of hypertension have been linked to the D allele.[65]

Blood pressure regulation via ACE gene variations is a complicated matter involving multiple processes. Higher activity of ACE involving D-allele of ACE gene leads to increased angiotensin-II production.[65] The consequence is vasoconstriction, and retaining of salts and water resulting into high blood pressure.[64] In addition, the D allele is associated with higher levels of oxidative stress and inflammation which increase the risk of hypertension.[66]

Given that the ACE gene plays a pivotal role in elevating blood pressure, targeting this pathway for possible therapy stands out as essential. Blocking the action of an ACE inhibitor class of antihypertensive drugs results in decreased production of angiotensin II and vasodilatation. Antihypertensive drugs have proved effective in reducing blood pressure and decreasing the chances of a cardiovascular event among hypertensive patients.

AGT gene

Another important member of RAAS is the AGT gene or the angiotensinogen gene. It codes for angiotensinogen, a precursor to angiotensin I produced by renin triggering the RAAS cascade. The ACE enzyme converts angiotensin I to angiotensin II.[67]

Variations in AGT genes were found and analyzed concerning changes in blood levels of angiotensinogen. An example of this type of variation is the M235Tpolymorphism where Threonine [T] substitutes for

Methionine [M] at 235site in the Angiotensinogen gene.[68] Individuals carrying the T allele have been found to produce more angiotensinogen and therefore are at a greater risk for hypertension. [69-70]

Increased production of angiotensin II is the link between AGT gene variants and hypertension. M235M variant of the M235T polymorphism carries elevated angiotensinogen levels which leads to more intense conversion to angiotensin I and subsequently produces more angiotensin II. This causes vasoconstriction, sodium and water retention and raised blood pressure.[70]

Interventions directed at the AGT gene pathway are designed to lower angiotensin II production that leads to elevated blood pressure. ARBs act by blocking the interaction between angiotensin II and its receptors thereby stopping its vasoconstrictive and sodium retaining effects.[71] On another level, an alternative approach is using renin inhibitors that focus on the blocking of renin, enzyme that converts angiotensinogen into angiotensin I. Interventions like these have displayed positive results with respect to reduction of BP and cardiovascular risks in subjects of high blood pressure.[71]

NPPA/NPPB Genes

Atrial natriuretic peptide (ANP) is encoded by the NPPA gene while B-type natriuretic peptide (BNP) is encoded by NPPB genes.[72] They are important peptides involved in the regulation of blood pressure and body fluids through promotion of natriuresis and diuresis in the kidneys. Angiotensin II has vasoconstrictive actions, but these are opposed by the actions of ANP and BNP with their vasodilatory effects.[72]

Association between genetic variants in NPPA/NPPB genes and hypertension has been examined. Examples of such polymorphisms include the T2238C SNP in the NPPA gene and the T-381C SNP in the NPPB gene.[73] Variants in these genes are associated with changes in ANP and BNP levels and higher chances of hypertension. ANP and BNP levels are modulated in relation to the interplay between NPPA/NPPB gene variants and blood pressure regulation. The lower ANP levels have been associated with the T2238C SNP in the NPPA gene while the T-381C SNP in the NPPB gene corresponds to the reduced concentration of BNP.74 Such changes in peptides may interrupt the equilibrium between vasoconstrictor and vasodilator elements leading to rise in blood pressure. [74-75]

On the other hand, one of the possible therapeutic approaches for hypertension based on NPPA/NPPB genes may include administration of extracellular ANP and BNP antagonists as additives to address deficits of these peptides.[75] Another way to treat CHF involves developing new pharmaceuticals that would stimulate the synthesis or release of ANP and BNP. Both methods are geared towards the same end of restoring the equilibrium between vasoconstriction and vasodilation, which would result in a lowering blood pressure.[75]

CYP11B2 Gene

Aldosterone synthase, the final step in the synthesis of the hormone aldosterone, which is important in sodium-water balance, is encoded by the CYP11B2 gene.[76] Elevated blood volume and hypertension are a consequence of aldosterone's action on the kidneys, facilitating salt reabsorption and potassium excretion.

The effect of CYP11B2 genetic variants on aldosterone production has been

investigated. The C-344T polymorphism at position 344 of the CYP11B2 gene is one such mutation. It involves the substitution of thymine (T) for cytosine (C). In addition to increased risk of hypertension, the T allele is associated with elevated aldosterone levels.[76]

Aldosterone synthase gene (CYP11B2) polymorphisms have been linked to high blood pressure and BP. Additionally, T carriers of the CYP11B2 344 C/T polymorphism showed higher urinary aldosterone excretion.[77] This process results in a cascade of sodium and water retention, expansion of blood volumes and ultimately, high blood pressure.

Elucidation of the CYP11B2 gene pathway provides opportunities for the development of focused pharmacological interventions which may minimize the influence of aldosterone on blood pressure. Spironolactone and eplerenone are MRAs (mineralocorticoid receptor antagonists). These drugs block the binding of aldosterone with its receptors, which leads to decreased sodium reabsorption and potassium excretion. Thus, these drugs have succeeded clinically in lowering the blood pressure of persons affected by hypertension.

Other Candidate Genes

Many more potential genes have also been linked to hypertension, in addition to the ACE, AGT, NPPA/NPPB, and CYP11B2 genes. These genes play a role in oxidative stress and vascular remodeling, among other physiological processes. Oxidative stress and vascular remodeling genes may have an impact on blood pressure regulation.[78] Increased oxidative stress, inflammation, and vascular remodeling may be caused by variations in these genes, which may in turn contribute to hypertension.[78]

Expanding our knowledge of the intricate genetic basis of hypertension requires more research into other potential genes that have been linked to the disorder. We can discover novel mechanisms and potential therapeutic targets for the treatment of hypertension by discovering and researching these genes.

GWAS FINDINGS AND HYPERTENSION

Challenges in Identifying Genetic Variants Associated with BP:

Early attempts to identify genetic variants associated with BP were challenging and yielded relatively low results. The first genome-wide association study (GWAS) conducted in 2007 by the Welcome Trust Case Control Consortium (WTCCC) did not find any significant results for hypertension.[79] Similarly, the Framingham Heart Study, which included 1,400 family subjects, also found no significant results for quantitative BP phenotypes.[80] These studies highlighted the complexity of the genetic mechanisms underlying BP regulation and the need for larger sample sizes to identify genes associated with BP and hypertension.

Enhancing Statistical Power and Success in GWAS:

To enhance statistical power, international collaborations and consortia were established between studies. Additionally, focusing on associations with BP as a continuous variable rather than in case-control studies proved to be successful. In 2009, two large-scale meta-analyses conducted by the Global Blood Pressure Genetics (Global BPgen) [81]and Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)[82] consortia identified associations withstanding correction for multiple testing. These studies

included nearly 30,000 subjects at the discovery phase and found eight genomic loci, with three loci overlapping. The International Consortium for Blood Pressure (ICBP)[83] replicated these loci and discovered 16 new loci significant at the genome-wide level. Subsequent GWAS studies, including the UK Biobank participants, further expanded the number of significant loci associated with systolic BP, diastolic BP, and pulse pressure.[84]

Genetic Variants Associated with BP in East Asian Populations:

The first large meta-analysis of GWAS on BP traits among East Asians was conducted by the Asian Genetic Epidemiology Network (AGEN) consortium.[85] This study confirmed seven loci previously identified in the European population and identified six novel loci specific to East Asians. Another meta-analysis in a Han Chinese population replicated eight previously reported loci and discovered four novel loci.[86] These findings suggest the presence of allelic heterogeneity in BP regulation between Europeans and Asians, providing new mechanistic insights into hypertension.

Genetic Variants Associated with BP in African-descent Populations:

African-descent populations, being the most ancestral, have smaller regions of linkage disequilibrium due to the accumulation of more recombination events. GWAS performed on Africans require more single nucleotide polymorphisms (SNPs) with better overall genomic coverage.[87] Consequently, there are fewer loci reaching GWAS significance in African populations compared to Europeans or Asians. The largest GWAS performed in an African-origin population identified nine loci with 11 independent variants associated with SBP, DBP, hypertension, or combined traits.[88]

The genetics of blood pressure regulation is a complex and multifactorial process. GWAS studies have made significant progress in identifying genetic variants associated with BP, particularly in European and Asian populations. These findings have shed light on the mechanistic insights into hypertension and have the potential to improve the diagnosis, control, and treatment of cardiovascular diseases. However, further research is needed, particularly in African-descent populations, to fully understand the genetic factors contributing to blood pressure regulation and hypertension.

CLINICAL IMPLICATIONS

Genome-wide association studies (GWAS) have revolutionized our comprehension of the genetic elements that impact the regulation of blood pressure (BP). In recent research,84 numerous significant loci linked to BP have been identified, shedding light on genes such as angiotensin-converting enzymes, voltage-dependent calcium channel auxiliary subunit, metallo-endopeptidase/neutral endopeptidase, adrenergic β 2B receptor, and phosphodiesterase 5a. Moreover, through pathway analysis, scientists have discovered associations with pathways directly related to cardiovascular disease. These findings, generated by human intellect and scientific exploration, have greatly enhanced our understanding of the intricate mechanisms governing BP regulation.

Impact of GWAS on Hypertension Risk Assessment:

The ICBP GWAS study [89] revealed a compelling correlation between an

individual's genetic risk score (GRS) and their blood pressure levels. The researchers found that those with higher GRS experienced significantly elevated systolic and diastolic blood pressure (SBP and DBP) compared to individuals with lower GRS. In fact, the difference in SBP and DBP between the top and bottom quintiles of the GRS was measured at 4.6- and 3.0-mm Hg, respectively. These findings suggest that GRS could serve as a valuable tool in assessing hypertension risk and guiding early lifestyle modifications.

Personalized Prevention and Treatment

The GWAS findings have also provided insights into personalised prevention and treatment strategies for hypertension. For example, the uromodulin gene (UMOD) has been associated with a lower risk of hypertension and reduced urinary UMOD excretion.[90] Uromodulin influences blood pressure through its effect on sodium hemostasis, and its modulation presents an opportunity for precision medicine and new drug development.[91]

Ethnicity-Specific Loci and Pleiotropic Effects

The AGEN study[85] identified an ethnicity-specific locus on 12q24.13, where the acetaldehyde dehydrogenase (ALDH2) gene is located. This gene plays a key role in alcohol metabolism,[92] and certain variants result in an inability to metabolise acetaldehyde, leading to its accumulation. Interestingly, this locus exhibits a deleterious effect on blood pressure but has protective effects on HDL and LDL cholesterol, resulting in a net reduction in cardiovascular disease risk.

While GWAS have provided valuable insights, they explain only a small proportion of the observed variation in traits such as BP. Next-generation sequencing and studies on gene-environment and gene-gene interactions may help uncover additional genetic factors. Genetic screening tests, although available through direct-to-consumer companies, have limited clinical utility at present. However, the future application of genetic screening lies in identifying risk groups early in life and guiding targeted preventive measures and pharmacogenetic tests. In conclusion, GWAS have significantly contributed to our understanding of hypertension's genetic basis, identifying potential personalised prevention and treatment targets. While their clinical utility is currently restricted, ongoing research and advancements in genetic screening technology offer hope for improved risk assessment and the guidance of preventive measures in the future.[93]

Future Prospective

Further research is needed to identify additional genetic variants associated with hypertension, particularly in underrepresented populations such as African-descent populations. This will help improve our understanding of the genetic factors contributing to blood pressure regulation and hypertension across diverse populations.

The integration of genetic information into routine healthcare practice holds promise for personalized medicine approaches in hypertension management. Genetic testing can help identify individuals at risk of developing hypertension and guide medication selection and dosage for optimal blood pressure control. Continued research into the underlying mechanisms of hypertension, such as the renin-angiotensin-aldosterone system, endothelial dysfunction, oxidative stress, and sodium and potassium transport genes, can lead to the development

of more targeted and effective therapeutic strategies. The use of genetic information to tailor lifestyle interventions, such as dietary recommendations and physical activity plans, can improve blood pressure control and treatment outcomes. Further research is needed to explore the effectiveness and feasibility of implementing personalized lifestyle interventions based on genetic information. The translation of genetic findings into clinical practice poses challenges, including the need for standardized genetic testing protocols, integration of genetic information into electronic health records, and education of healthcare providers on the interpretation and application of genetic information.

LIMITATIONS

Many studies on genetic factors in hypertension have focused on specific populations, limiting the generalizability of the findings. More diverse and larger-scale studies are needed to validate the associations across different ethnic groups. The complex interplay between genetic and environmental factors in hypertension requires further investigation. Future research should aim to understand the interactions between genetic variations and lifestyle factors, such as diet, physical activity, and stress, in the development and progression of hypertension. The translation of genetic findings into clinical practice is still in its early stages. Standardized protocols for genetic testing, guidelines for interpretation of genetic information, and integration of genetic information into routine healthcare are needed to fully realize the potential of personalized medicine in hypertension management.

The current understanding of the genetic factors involved in hypertension is incomplete. There may be additional genetic variants and pathways yet to be discovered that contribute to blood pressure regulation and hypertension risk. The impact of genetic variations on treatment response and medication efficacy in hypertension is still being explored. Further research is needed to determine the clinical utility of genetic testing in guiding medication selection and dosage for optimal blood pressure control. Ethical considerations, such as privacy and confidentiality of genetic information, need to be addressed when implementing genetic testing in clinical practice. Clear guidelines and regulations are necessary to ensure the responsible and ethical use of genetic information in healthcare.

CONCLUSION

In conclusion, hypertension is a complex and multifactorial condition influenced by both genetic and environmental factors. Genetic factors play a significant role in the development and progression of hypertension, with heritability estimates suggesting that approximately 30-50% of blood pressure variation can be attributed to genetic factors.

Studies have identified several genetic polymorphisms associated with hypertension, particularly within genes involved in the renin-angiotensin-aldosterone system (RAAS), endothelial nitric oxide synthase (eNOS), alpha-adducin (ADD1), beta-adrenergic receptors (ADRB), sodium and potassium transport genes (ATP1A1 and SLC12A2), and others. These genetic variations can impact blood pressure regulation, sodium reabsorption, vascular tone, and responses to antihypertensive medications.

Genetic testing has shown promise in identifying individuals at risk of developing hypertension and guiding personalized treatment approaches. By analyzing specific

genetic variations, healthcare providers can tailor medication selection and dosage, leading to improved blood pressure control and treatment outcomes.

Additionally, studies into possible therapeutic targets for hypertension, including RAAS, endothelial dysfunction, oxidative stress, and others, present chances for the creation of more efficient and individualised therapies. Targeting these underlying mechanisms can assist in addressing the underlying causes of hypertension and enhance patient outcomes.

Overall, developing novel therapeutic approaches and applying personalised medicine techniques will be greatly aided by a thorough understanding of the genetic factors associated with hypertension. Healthcare professionals can optimise hypertension management and enhance patient outcomes by taking into account unique genetic and lifestyle factors. Further research is needed to fully elucidate the genetic underpinnings of hypertension and translate these findings into clinical practice.

Declaration by Authors

Ethical Approval: Not Applicable
Acknowledgement: None
Source of Funding: None
Conflict of Interest: The authors declare no conflict of interest.

REFERENCES

1. Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nature Reviews Cardiology. 2021 May 28;18(18).)
2. Farhadi F, Roqayeh Aliyari, Ebrahimi H, Hashemi H, Mohammad Hassan Emamian, Akbar Fotouhi. Prevalence of uncontrolled hypertension and its associated factors in 50–74 years old Iranian adults: a population-based study. 2023 Jun 24;23(1).
3. Kuneš J, Zicha J. The interaction of genetic and environmental factors in the etiology of hypertension. Physiological research. 2009;58(2):33-42
4. Phillips C. Nutrigenetics and Metabolic Disease: Current Status and Implications for Personalised Nutrition. Nutrients. 2013 Jan 10;5(1):32–57
5. Bellia, A.; Giardina, E.; Lauro, D.; Tesauro, M.; Di Fede, G.; Cusumano, G.; Federici, M.; Rini, G.B.; Novelli, G.; Lauro, R.; et al. "The linosa study": Epidemiological and heritability data of the metabolic syndrome in a caucasian genetic isolate. Nutr. Metab. Cardiovasc. Dis. 2009, 19, 455–461. [Google Scholar] [CrossRef]
6. Henneman, P.; Aulchenko, Y.S.; Frants, R.R.; van Dijk, K.W.; Oostra, B.A.; van Duijn, C.M. Prevalence and heritability of the metabolic syndrome and its individual components in a dutch isolate: The erasmus rucphen family study. J. Med. Genet. 2008, 45, 572–577.
7. Hypertension: MedlinePlus Genetics [Internet]. medlineplus.gov.
8. Weder AB. Genetics and hypertension. Journal of Clinical Hypertension (Greenwich, Conn) [Internet]. 2007 Mar 1 [cited 2021 Oct 3];9(3):217–23.
9. Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. Trends in cardiovascular medicine. 2020 Apr 1;30(3):160-4.
10. Kim D, Yang PS, Kim TH, Jang E, Shin H, Kim HY, Yu HT, Uhm JS, Kim JY, Pak HN, Lee MH. Ideal blood pressure in patients with atrial fibrillation. Journal of the American College of Cardiology. 2018 Sep 11;72(11):1233-45.
11. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nature Reviews Nephrology. 2020 Feb 5;16(4):223–37.
12. Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. European Heart Journal. 2013 Jan 9;34(13):951–61.
13. Ji L, Cai X, Zhang L, Fei L, Wang L, Su J, Lazar L, Xu J, Zhang Y. Association between polymorphisms in the renin-angiotensin-aldosterone system genes and essential hypertension in the Han Chinese population. PloS one. 2013 Aug 28;8(8).
14. Davis J, Oparil S. Novel medical treatments for hypertension and related comorbidities. Current hypertension reports. 2018 Oct; 20:1-7.

15. .Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1)(dipeptidyl carboxypeptidase 1). Nucleic acids research. 1992 Mar 3;20(6):1433.
16. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. The Journal of clinical investigation. 1990 Oct 1;86(4):1343-6
17. Danser AJ, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA, Schunkert H. Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation. 1995 Sep 15;92(6):1387-8.
18. Bedir A, Arık N, Adam B, Kılınç K, Gümüş T, Güner E. Angiotensin converting enzyme gene polymorphism and activity in Turkish patients with essential hypertension. American journal of hypertension. 1999 Oct 1;12(10):1038-43
19. Di Pasquale P, Cannizzaro S, Paterna S. Does angiotensin-converting enzyme gene polymorphism affect blood pressure? Findings after 6 years of follow-up in healthy subjects. European journal of heart failure. 2004 Jan;6(1):11-6.
20. Han C, Han XK, Liu FC, Huang JF. Ethnic differences in the association between angiotensin-converting enzyme gene insertion/deletion polymorphism and peripheral vascular disease: a meta-analysis. Chronic diseases and translational medicine. 2017 Dec 1;3(4):230-41
21. Mopidevi B, Kaw MK, Sivankutty I, Jain S, Perla SK, Kumar A. A polymorphism in intron I of the human angiotensinogen gene (hAGT) affects binding by HNF3 and hAGT expression and increases blood pressure in mice. Journal of Biological Chemistry. 2019 Aug 1;294(31):11829-39
22. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, Cheng T, Ludwig EH, Sharma AM, Hata A, Jeunemaitre X. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. The Journal of clinical investigation. 1997 Apr 1;99(7):1786-97
23. Chandra S, Narang R, Sreenivas V, Bhatia J, Saluja D, Srivastava K. Association of angiotensin II type 1 receptor (A1166C) gene polymorphism and its increased expression in essential hypertension: a case-control study. PloS one. 2014 Jul 3;9(7):e101502
24. Feldman RD. Aldosterone and blood pressure regulation: recent milestones on t he long and winding road from electrocortin to KCNJ5, GPER, and beyond. Hypertension. 2014 Jan;63(1):19-21
25. Takeuchi F, Yamamoto K, Katsuya T, Sugiyama T, Nabika T, Ohnaka K, Yamaguchi S, Takayanagi R, Ogihara T, Kato N. Reevaluation of the association of seven candidate genes with blood pressure and hypertension: a replication study and meta-analysis with a larger sample size. Hypertension Research. 2012 Aug;35(8):825-31
26. Sun J, Zhao M, Miao S, Xi B. Polymorphisms of three genes (ACE, AGT and CYP11B2) in the renin–angiotensin–aldosterone system are not associated with blood pressure salt sensitivity: A systematic meta-analysis. Blood pressure. 2016 Mar 3;25(2):117-22
27. Fatini C, Sticchi E, Sofi F, Said AA, Pratesi G, Pulli R, Pratesi C, Abbate R. Multilocus analysis in candidate genes ACE, AGT, and AGTR1 and predisposition to peripheral arterial disease: role of ACE D/-240T haplotype. Journal of vascular surgery. 2009 Dec 1;50(6):1399-404
28. Tošić JS, Đurić Ž, Popović J, Buzadžić I, Dimković S, Dimković N. Polymorphism of angiotensin converting enzyme in hemodialysis patients-association with cardiovascular morbidity. Medicinski pregled. 2014;67(9-10):297-304
29. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, Van Duijn CM, Witteman JC. ACE polymorphisms. Circulation research. 2006 May 12;98(9):1123-33.
30. Gambano G, Anglani F, D'Angelo A. Association studies of genetic polymorphisms and complex disease. The Lancet. 2000 Jan 22;355(9200):308-11
31. Tran N, Garcia T, Aniqa M, Ali S, Ally A, Nauli SM. Endothelial Nitric Oxide Synthase (eNOS) and the Cardiovascular System: in Physiology and in Disease States. American journal of biomedical

science & research [Internet]. 2022; 15(2):153–77.
32. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. European heart journal. 2012;33(7):829–37
33. Rapoport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature. 1983 Nov 10;306(5939):174-6.
34. Ahmad A, Dempsey SK, Daneva Z, Azam M, Li N, Li PL, et al. Role of Nitric Oxide in the Cardiovascular and Renal Systems. International Journal of Molecular Sciences [Internet]. 2018 Sep 3;19(9).
35. Doris PA. Hypertension genetics, single nucleotide polymorphisms, and the common disease: common variant hypothesis. Hypertension. 2002 Feb 1;39(2):323-31.
36. Rossi GP, Taddei S, Virdis A, Cavallin M, Ghiadoni L, Favilla S, Versari D, Sudano I, Pessina AC, Salvetti A. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. Journal of the American College of Cardiology. 2003 Mar 19;41(6):938-45.
37. Ogretmen Z, Hiz MM, Silan F, Uludag A, Ozdemir O. Association of endothelial nitric oxide synthase Glu298Asp gene polymorphism in psoriasis cases with hypertension. Annals of Saudi medicine. 2014 Jul;34(4):340-5.
38. Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. American journal of epidemiology. 2006 Nov 15;164(10):921-35.
39. Senturk N, Kara N, Aydin F, Gunes S, Yuksel EP, Canturk T, Bagci H, Turanli AY. Association of eNOS gene polymorphism (Glu298Asp) with psoriasis. Journal of dermatological science. 2006 Oct 1;44(1):52-5.
40. Thameem F, Puppala S, Arar NH, Stern MP, Blangero J, Duggirala R, Abboud HE. Endothelial nitric oxide synthase (eNOS) gene polymorphisms and their association with type 2 diabetes-related traits in Mexican Americans. Diabetes and Vascular Disease Research. 2008 Jun;5(2):109-13.
41. Lembo G, De Luca N, Battagli C, Iovino G, Aretini A, Musicco M, Frati G, Pompeo F, Vecchione C, Trimarco B. A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis. Stroke. 2001 Mar;32(3):735-40.
42. Moe KT, Lim ST, Wong P, Chua T, DeSilva DA, Koh TH, Wong MC, Chin-Dusting J. Association analysis of endothelial nitric oxide synthase gene polymorphism with primary hypertension in a Singapore population. Journal of human hypertension. 2006 Dec;20(12):956-63.
43. Wu Y, Ding Y, Ramprasath T, Zou MH. Oxidative stress, GTPCH1, and endothelial nitric oxide synthase uncoupling in hypertension. Antioxidants & redox signaling. 2021 Mar 20;34(9):750-64.
44. Bianchi G. Genetic variations of tubular sodium reabsorption leading to “primary” hypertension: from gene polymorphism to clinical symptoms. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2005 Dec; 289(6):R1536-49.
45. Li TF, Ke XY, Zhang YR, Zhan JH. The correlation between rs2501577 gene polymorphism and biliary atresia: a systematic review and meta-analysis. Pediatric Surgery International. 2023 May 29;39(1):206.
46. Yermolenko S, Chumachenko Y, Orlovskyi V, Moiseyenko I, Orlovskyi O. The association between Gly460Trp-polymorphism of Alpha-Adducin 1 Gene (ADD1) and arterial hypertension development in ukrainian population. International Journal of Hypertension. 2021 May 4; 2021:1-9.
47. Montani JP, Van Vliet BN. Understanding the contribution of Guyton's large circulatory model to long-term control of arterial pressure. Experimental physiology. 2009 Apr 1;94(4):382-8.
48. Ramu P, Umamaheswaran G, Shewade DG, Swaminathan RP, Balachander J, Adithan C. Gly460Trp polymorphism of the ADD1 gene and essential hypertension in an Indian population: A meta-analysis on hypertension risk. Indian Journal of Human Genetics. 2010 Jan;16(1):8.
49. Katsuya T, Ishikawa K, Sugimoto K, Rakugi H, Ogihara T. Salt sensitivity of Japanese from the viewpoint of gene

polymorphism. Hypertension research. 2003;26(7):521-5.
50. Ferrari P, Ferrandi M, Valentini G, Bianchi G. Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+-ATPase alterations in ouabain and adducin-dependent hypertension. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2006 Mar;290(3):R529-35.
51. Svetkey LP, Harris EL, Martin E, Vollmer WM, Meltesen GT, Ricchiuti V, Williams G, Appel LJ, Bray GA, Moore TJ, Winn MP. Modulation of the BP response to diet by genes in the renin–angiotensin system and the adrenergic nervous system. American journal of hypertension. 2011 Feb 1;24(2):209-17.
52. Zhu H, Poole J, Lu Y, Harshfield G, Treiber F, Snieder H, Dong Y. Sympathetic nervous system, genes and human essential hypertension. Current neurovascular research. 2005 Oct 1;2(4):303-17.
53. Mahata SK, Kiranmayi M, Mahapatra NR. Catestatin: a master regulator of cardiovascular functions. Current medicinal chemistry. 2018 Apr 1;25(11):1352-74.
54. De Faire U. Adrenoreceptor genes and hypertension: contribution from genetic polymorphisms. Journal of hypertension. 2002 Jun 1;20(6):1047-8.
55. Wang H, Liu J, Liu K, Liu Y, Wang Z, Lou Y, Niu Q, Gu W, Wang L, Li M, Zhu X. β1-adrenoceptor gene Arg389Gly polymorphism and essential hypertension risk in general population: a meta-analysis. Molecular biology reports. 2013 Jun; 40:4055-63.
56. Pacanowski MA, Gong Y, Cooper-DeHoff RM, Schork NJ, Shriver MD, Langaee TY, Pepine CJ, Johnson JA. β-adrenergic receptor gene polymorphisms and β-blocker treatment outcomes in hypertension. Clinical Pharmacology & Therapeutics. 2008 Dec;84(6):715-21.
57. Bunker-Wiersma HE, Koopmans RP, Kuipers TW, Knoester H, Bos AP. Single nucleotide polymorphisms in genes of circulatory homeostasis in surviving pediatric intensive care patients with meningococcal infection. Pediatric Critical Care Medicine. 2008 Sep 1;9(5):517-23.
58. Snyder EM, Sprissler R, Olson TP. The importance of use of genetics to guide hypertension therapy: using β-blockade as an example. Advances in Molecular Pathology. 2021 Nov 1; 4:117-25.
59. Clausen MJ, Poulsen H. Sodium/potassium homeostasis in the cell. Metallomics and the Cell. 2013:41-67.
60. Mukherji ST. Role of Na/K-ATPase Non-enzymatic Signaling in Renal Proximal Tubule Sodium Transport.
61. Bazúa-Valenti S, Castañeda-Bueno M, Gamba G. Physiological role of SLC12 family members in the kidney. American Journal of Physiology-Renal Physiology. 2016 Jul 1;311(1):F131-44.
62. Meor Azlan NF, Zhang J. Role of the cation-chloride-cotransporters in cardiovascular disease. Cells. 2020 Oct 14;9(10):2293.
63. Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AJ. Hypertension: renin–angiotensin–aldosterone system alterations. Circulation research. 2015 Mar 13;116(6):960-75.
64. Melake A, Berhane N. Angiotensin-converting enzyme gene insertion/deletion polymorphism and risk of ischemic stroke complication among patients with hypertension in the Ethiopian population. Frontiers in Neurology. 2023 Mar 22; 14:1093993.
65. Baghai TC, Binder EB, Schule C, Salyakina D, Eser D, Lucae S, Zwanzger P, Haberger C, Zill P, Ising M, Deiml T. Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Molecular psychiatry. 2006 Nov; 11(11):1003-15.
66. Kayashima Y, Smithies O, Kakoki M. Kinins - the kallikrein-kinin system and oxidative stress. Current opinion in nephrology and hypertension. 2012 Jan;21(1):92.
67. Shahid M, Rehman K, Akash MS, Suhail S, Kamal S, Imran M, Assiri MA. Genetic polymorphism in angiotensinogen and its association with cardiometabolic diseases. Metabolites. 2022 Dec 19;12(12):1291.
68. Zhen Z, Gao L, Wang Q, Chen X, Na J, Xu X, Yuan Y. Angiotensinogen M235T polymorphism and susceptibility to hypertrophic cardiomyopathy in Asian population: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 2020 Oct-Dec;21(4)

69. Glavnik N, Petrovic D. M235T polymorphism of the angiotensinogen gene and insertion/deletion polymorphism of the angiotensin-1 converting enzyme gene in essential arterial hypertension in Caucasians. Folia Biol (Praha). 2007;53(2):69-70.
70. Mondry A, Loh M, Liu P, Zhu AL, Nagel M. Polymorphisms of the insertion / deletion ACE and M235T AGT genes and hypertension: surprising new findings and meta-analysis of data. BMC Nephrol. 2005 Jan 11
71. Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013;19(17)
72. Salo PP, Havulinna AS, Tukiainen T, Raitakari O, Lehtimäki T, Kähönen M, Kettunen J, Männikkö M, Eriksson JG, Jula A, Blankenberg S. Genome-wide association study implicates atrial natriuretic peptide rather than B-type natriuretic peptide in the regulation of blood pressure in the general population. Circulation: Cardiovascular Genetics. 2017 Dec;10(6): e001713.
73. Rubattu S, Sciarretta S, Volpe M. Atrial natriuretic peptide gene variants and circulating levels: implications in cardiovascular diseases. Clinical Science. 2014 Jul 1;127(1):1-3.
74. Vassalle C, Andreassi MG. Genetic polymorphisms of the natriuretic peptide system in the pathogenesis of cardiovascular disease: what lies on the horizon? Clinical chemistry. 2009 May 1;55(5):878-87.
75. S. Jeson Sangaralingham, Kühn M, Cannone V, Chen HH, Burnett JC. Natriuretic peptide pathways in heart failure: further therapeutic possibilities. Cardiovascular Research 2022 Aug 25;118(18):3416–33
76. Rajput C, Makhijani K, Norboo T, Afrin F, Sharma M, Pasha ST, Pasha MA. CYP11B2 gene polymorphisms and hypertension in highlanders accustomed to high salt intake. Journal of hypertension. 2005 Jan 1;23(1):79-86.
77. Fontana V, de Faria AP, Barbaro NR, Sabbatini AR, Modolo R, Lacchini R, Moreno H. Modulation of aldosterone levels by− 344 C/T CYP11B2 polymorphism and spironolactone use in resistant hypertension. Journal of the American Society of Hypertension. 2014 Mar 1;8(3):146-51.
78. Sena CM, Leandro A, Azul L, Seiça R, Perry G. Vascular Oxidative Stress: Impact and Therapeutic Approaches. Front Physiol. 2018 Dec 4; 9:1668.
79. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007 Jun 7;447(7145):661-78.
80. Levy D, Larson MG, Benjamin EJ, Newton-Cheh C, Wang TJ, Hwang SJ, et al. Framingham Heart Study 100K Project: genome-wide associations for blood pressure and arterial stiffness. *BMC Med Genet.* 2007 Sep;8
81. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al.Wellcome Trust Case Control Consortium Genome-wide association study identifies eight loci associated with blood pressure. *Nat Genet.* 2009 Jun;41((6)):666–76.
82. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. *Nat Genet.* 2009 Jun;41((6)):677–87.
83. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al.CHARGE-HF consortium Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature.* 2011 Sep;478((7367)):103–9.
84. Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, et al.International Consortium of Blood Pressure (ICBP) 1000G Analyses. BIOS Consortium. Lifelines Cohort Study. Understanding Society Scientific group. CHD Exome+ Consortium. ExomeBP Consortium. T2D-GENES Consortium. GoT2DGenes Consortium. Cohorts for Heart and Ageing Research in Genome Epidemiology (CHARGE) BP Exome Consortium. International Genomics of Blood Pressure (iGEN-BP) Consortium. UK Biobank CardioMetabolic Consortium BP working group Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nat Genet.* 2017 Mar;49((3)):403–15.
85. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, et al. Meta-analysis of genome-wide association studies identifies

common variants associated with blood pressure variation in east Asians. *Nat Genet.* 2011 Jun;43((6)):531–8.
86. Lu X, Wang L, Lin X, Huang J, Charles Gu C, He M, et al. Genome-wide association study in Chinese identifies novel loci for blood pressure and hypertension. *Hum Mol Genet.* 2015 Feb;24(3):865–74.
87. Bush WS, Moore JH. Chapter 11: genome-wide association studies. *PLOS Comput Biol.* 2012;8((12)):e1002822.
88. Liang J, Le TH, Edwards DR, Tayo BO, Gaulton KJ, Smith JA, et al. Single-trait and multi-trait genome-wide association analyses identify novel loci for blood pressure in African-ancestry populations. *PLoS Genet.* 2017 May;13(5)
89. Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD, et al.LifeLines Cohort Study. EchoGen consortium. AortaGen Consortium. CHARGE Consortium Heart Failure Working Group. KidneyGen consortium. CKDGen consortium. Cardiogenics consortium. CardioGram Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. *Nat Genet.* 2011 Sep;43((10))
90. Padmanabhan S, Melander O, Johnson T, Di Blasio AM, Lee WK, Gentilini D, et al. Global BPgen Consortium Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. *PLoS Genet.* 2010 Oct;6((10))
91. Trudu M, Janas S, Lanzani C, Debaix H, Schaeffer C, Ikehata M, et al.SKIPOGH team Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. *Nat Med.* 2013 Dec;19((12))
92. Takeshita T, Morimoto K, Mao XQ, Hashimoto T, Furuyama J. Phenotypic differences in low Km aldehyde dehydrogenase in Japanese workers. *Lancet.* 1993 Mar;341((8848)):837–8.
93. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE, Hong Y, Howard BV, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009; 119:2408–2416.

How to cite this article: Ramakrishna Shabaraya A, Trupthi D Shetty. Genetic factors associated with hypertension: a comprehensive review. *International Journal of Research and Review.* 2023; 10(11): 126-142.
DOI: *https://doi.org/10.52403/ijrr.20231115*

******